Efficacy and Mechanism of Action of Yiru Tiaojing Granule Against Hyperprolactinemia In Vitro and In Vivo

Abstract

Yiru Tiaojing Granule, a traditional Chinese medicine formula, is used to treat hyperprolactinemia. This study was conducted to evaluate the mechanism of action and pharmacological activity of Yiru Tiaojing Granule on prolactin secretion. The animal model of hyperprolactinemia was induced by metoclopramide. The dopamine D2 receptor in hyperprolactinemia rat models was analyzed by immunohistochemistry. The biochemical parameters, including a follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone, testosterone, and prolactin, were measured by an enzyme-linked immunosorbent assay. Furthermore, the expression of prolactin and the dopamine D2 receptor was analyzed by Western blotting. The components in the Yiru Tiaojing Granule-medicated serum were assayed by liquid chromatography-tandem mass spectrometry. The Yiru Tiaojing Granule significantly decreased the prolactin level in the hyperprolactinemia rat model, and increased the estradiol, luteinizing hormone, and progesterone levels. The high and medium doses of Yiru Tiaojing Granule reduced dopamine D2 receptor expression in the brain (p < 0.001) and produced a similar effect on bromocriptine (p < 0.001). Yiru Tiaojing Granule-medicated serum reduced (p < 0.001) prolactin expression in MMQ cells in a concentration-dependent manner, but had no effects on GH3 cells. The level of the dopamine D2 receptor in MMQ cells was also increased dose-dependently (p < 0.05). In addition, the protein kinase A and cyclic adenosine monophosphate in MMQ cells were significantly attenuated dose-dependently by treatment with a high and medium dose of Yiru Tiaojing Granule-medicated serum (p < 0.05) and bromocriptine-medicated serum (p < 0.01). The results suggested that Yiru Tiaojing Granule was effective against hyperprolactinemia, and the activation of the dopamine D2 receptor, which was related to the second messenger cyclic adenosine monophosphate and protein kinase A, might be the potential mechanism.

Key words

Yiru Tiaojing Granule - hyperprolactinemia - MMQ cell - GH3 cell - mechanism

^* These authors contributed equally to this work.

• References

• 1 Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999; 44: 1075-1084
• 2 Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 2010; 6: 243-246
• 3 Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 2003; 9: 344-353
• 4 Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11: 851-856
• 5 Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci 2013; 6: 168-175
• 6 Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002; 87: 3578-3582
• 7 Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11: 851-856
• 8 dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 2011; 14: 259-265
• 9 Wang C, Pan B, Liu J, Chen M. Clinical efficacy of Yiru Tiaojing Granules for hyperprolacfinemia of renal deficiency and liver stagnation type. China Pharmacy 2009; 18: 1421-1423
• 10 Moro M, Inada Y, Miyata H, Komatsu H, Kojima M, Tsujii H. Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats. Clin Exp Pharmacol Physiol 2001; 28: 651-658
• 11 Yin J, Luo Y, Deng H, Qin S, Tang W, Zeng L, Zhou B. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARalpha pathways in L02 cells and HepG2 cells. J Ethnopharmacol 2014; 154: 229-239
• 12 Zhang YH, Liu JT, Wen BY, Xiao XH. In vitro inhibition of proliferation of vascular smooth muscle cells by serum of rats treated with Dahuang Zhechong pill. J Ethnopharmacol 2007; 112: 375-379
• 13 Lin JM, Zhao JY, Zhuang QC, Hong ZF, Peng J. Xiongshao capsule promotes angiogenesis of HUVEC via enhancing cell proliferation and up-regulating the expression of bFGF and VEGF. Chin J Integr Med 2011; 17: 840-846
• 14 Koyama T, Ohara M, Ichimura M, Saito M. Effect of Japanese kampo medicine on hypothalamic-pituitary-ovarian function in women with ovarian insufficiency. Am J Chin Med 1988; 16: 47-55
• 15 Wang D, Wong HK, Zhang L, McAlonan GM, Wang XM, Sze SC, Feng YB, Zhang ZJ. Not only dopamine D2 receptors involved in peony-glycyrrhiza decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 332-338
• 16 Sakamoto K, Wakabayashi K. Inhibitory effect of glycyrrhetinic acid on testosterone production in rat gonads. Endocrinol Jpn 1988; 35: 333-342
• 17 Armanini D, Mattarello MJ, Fiore C, Bonanni G, Scaroni C, Sartorato P, Palermo M. Licorice reduces serum testosterone in healthy women. Steroids 2004; 69: 763-766
• 18 Takeuchi T, Nishii O, Okamura T, Yaginuma T. Effect of paeoniflorin, glycyrrhizin and glycyrrhetic acid on ovarian androgen production. Am J Chin Med 1991; 19: 73-78
• 19 Vijayanarayana K, Rodrigues RS, Chandrashekhar KS, Subrahmanyam EV. Evaluation of estrogenic activity of alcoholic extract of rhizomes of Curculigo orchioides . J Ethnopharmacol 2007; 114: 241-245
• 20 Li Y, Lu SS, Tang GY, Hou M, Tang Q, Zhang XN, Chen WH, Chen G, Xue Q, Zhang CC, Zhang JF, Chen Y, Xu XY. Effect of Morinda officinalis capsule on osteoporosis in ovariectomized rats. Chin J Nat Med 2014; 12: 204-212
• 21 Meador-Woodruff JH, Mansour A, Healy DJ, Kuehn R, Zhou QY, Bunzow JR, Akil H, Civelli O, Watson jr. SJ. Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacol 1991; 5: 231-242
• 22 Chen JF, Aloyo VJ, Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience 1993; 54: 669-680
• 23 Liu DZ, Zhu J, Jin DZ, Zhang LM, Ji XQ, Ye Y, Tang CP, Zhu XZ. Behavioral recovery following sub-chronic paeoniflorin administration in the striatal 6-OHDA lesion rodent model of Parkinsonʼs disease. J Ethnopharmacol 2007; 112: 327-332
• 24 Jang EY, Choe ES, Kim SC, Lee JR, Kim SG, Jeon JP, Buono RJ, Yang CH. Isoliquiritigenin suppresses cocaine-induced extracellular dopamine release in rat brain through GABA(B) receptor. Eur J Pharmacol 2008; 587: 124-128
• 25 Chen DL, Zhang P, Lin L, Zhang HM, Deng SD, Wu ZQ, Ou S, Liu SH, Wang JY. Protective effects of bajijiasu in a rat model of Abeta(2)(5)(−)(3)(5)-induced neurotoxicity. J Ethnopharmacol 2014; 154: 206-217
• 26 Ramirez AD, Smith SM. Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders. Cent Nerv Syst Agents Med Chem 2014; 14: 72-82
• 27 Zhao W, Huang Y, Liu Z, Cao BB, Peng YP, Qiu YH. Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway. PLoS One 2013; 8: e65860
• 28 Wang X, Ma L, Zhang EJ, Zou JL, Guo H, Peng SW, Wu JH. Water Extract of Fructus Hordei Germinatus shows antihyperprolactinemia activity via dopamine D2 receptor. Evid Based Complement Alternat Med 2014; 2014: 579054
• 29 Wang X, Li Y, Zhou H, Qin F, Wei Y, Wang L, Wang C. The quality standard of Yiru Tiaojing Granule. Chin Med Mat 2014; 37: 1273-1276